EICHORPublic-registry site landscape for NCT04489537, “Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B”, a Hemophilia A With Inhibitor study sponsored by Catalyst Biosciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04489537 (registry record) |
| Study title | Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B |
| Official title | Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On Demand Treatment and Control of Bleeding Episodes in Subjects With Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study |
| Sponsor | Catalyst Biosciences |
| Condition(s) | Hemophilia A With Inhibitor; Hemophilia B With Inhibitor |
| Phase | PHASE3 |
| Listed sites | 43 |
| Intervention(s) | MarzAA |
| Site countries | United States, Armenia, Georgia, Hungary, India, Italy, Malaysia, Mexico, Poland, Russia, South Africa, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT04489537.
Eichor generates a preliminary site-risk snapshot for NCT04489537 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Hemophilia A With Inhibitor studies · Weekly briefs
